Eli Lilly’s experimental gene-editing therapy, VERVE-102, has demonstrated the ability to reduce LDL cholesterol, the key driver of heart disease, by up to 62 percent in a single infusion. Tested in a Phase 1b trial involving 35 patients with inherited high cholesterol and early coronary artery disease, the one-time treatment targets the PCSK9 gene to switch off bad cholesterol production. Some patients maintained these reductions for as long as 18 months, potentially signaling a durable alternative to daily cholesterol drugs.
Eli Lilly’s VERVE-102 represents a potential breakthrough in cardiovascular care by offering a one-time gene-editing therapy that could deliver sustained reductions in low-density lipoprotein (LDL) cholesterol. LDL cholesterol, often dubbed the "bad" cholesterol, is a major contributor to coronary artery disease and cardiovascular deaths worldwide. The therapy works by targeting and editing the PCSK9 gene in liver cells, effectively turning off the production of PCSK9 protein, which normally inhibits the liver’s ability to clear LDL cholesterol from the bloodstream.
The Phase 1b Heart-2 trial, announced in May 2026, enrolled 35 patients diagnosed with inherited high cholesterol alongside premature coronary artery disease. These patients received a single infusion of VERVE-102. Results showed a reduction in LDL cholesterol levels of up to 62 percent. At the same time, circulating PCSK9 protein levels dropped by as much as 88 percent. Notably, some patients sustained these reductions for as long as 18 months following just one treatment.
Importantly, no treatment-related serious adverse events were reported in the trial, suggesting a favorable safety profile at this early stage. Sekar Kathiresan, Lilly’s senior vice president and co-founder of Verve Therapeutics, highlighted that The approach mimics naturally occurring genetic variants. Individuals with inactive PCSK9 genes naturally maintain lifelong low LDL cholesterol and significantly reduced heart attack risk.
VERVE-102 aims to replicate this protective effect through precise gene editing, potentially replacing the need for lifelong daily or injectable cholesterol-lowering medications.
Cardiovascular disease remains the leading cause of death globally, with coronary artery disease affecting over 300 million people worldwide. In the United States alone, it causes nearly 800,000 deaths annually.
Elevated LDL cholesterol is a central risk factor driving these numbers. Current standard treatments include statins and PCSK9 inhibitors, which require ongoing administration. Patient adherence to these regimens often poses challenges, limiting their overall effectiveness.
The prospect of a one-time gene-editing treatment like VERVE-102 could transform prevention strategies by providing durable cholesterol reduction without the burden of daily medication. That could especially benefit patients who struggle with adherence or have contraindications to existing drugs.
VERVE-102 emerged after Eli Lilly acquired Verve Therapeutics in 2025, reflecting a broader pharmaceutical industry trend toward gene-editing therapies aimed at chronic diseases beyond rare genetic disorders. This shift shows Lilly’s commitment to pioneering precision medicine approaches that alter disease pathways at the genetic level.
While the early Phase 1b results are promising, experts caution that larger and longer-term trials are essential to confirm the therapy’s durability, safety, and real-world effectiveness. Lilly has announced plans to initiate Phase 2 studies later in 2026, which will provide more robust data on VERVE-102’s potential as a standard treatment option.
Meanwhile, other pharmaceutical companies are also advancing genetically targeted cholesterol therapies. Novartis and Amgen are conducting trials on drugs that lower lipoprotein(a), or Lp(a), a genetically determined form of cholesterol particularly linked to increased heart attack risk. Some of these drugs have demonstrated the ability to reduce Lp(a) levels by more than 80 percent.
Market projections suggest these Lp(a)-lowering drugs could reach $5.6 billion in sales by 2032, assuming clinical benefits are confirmed. Novartis’s Phase 3 Horizon trial will probably report results around mid-2026, which may validate gene-targeted cholesterol reduction as a preventive cardiology tool.
The convergence of these developments signals a new frontier in cardiovascular disease treatment. By combining gene editing and precision medicine, pharmaceutical companies aim to address fundamental cardiovascular risk factors with therapies that could provide curative or long-lasting benefits, rather than symptom control.
Related Articles
The next critical step for VERVE-102 will be the completion and analysis of larger Phase 2 trials planned for late 2026. Alongside the release of late-stage data from competitors targeting Lp(a), these results will clarify whether one-time gene-editing therapies can become a mainstream option for preventing cardiovascular disease. For now, Eli Lilly’s early clinical data set a hopeful tone for durable cholesterol reduction.
